lucarista / Shutterstock.com
The English High Court has ruled that a patent covering Novartis’s transdermal patch treatment for Alzheimer’s disease, Exelon (rivastigmine), is invalid.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
English High Court, Novartis, Exelon, obviousness, patent invalidity, patent, Justice Richard Arnold